Vitamin E and Cardiovascular Disease

Summary

Interest in the use of antioxidants for the treatment of human disease, and in the role of dietary antioxidants in the prevention of disease development, has been sustained for at least two decades. Several anti-oxidant protective mechanisms exist and constitute a primary defensive system including enzymatic defences (glutathione peroxidase and superoxide dismutase, which depend on the presence of ions such as selenium, zinc, copper, and manganese) and naturally occurring vita-mins such as vitamin E, vitamin A, beta-carotene, and vitamin C. The most important natural antioxidants are vitamin E (in the form of α-, β-, γ-, and δ-tocopherols), beta-carotene, vitamin C and selenium (fundamental constituent of glutathione-peroxidase, i.e., an enzyme with antioxidant function). The first two are lipophilic substances whilst ascorbic acid is hydrophilic. Each antioxidant has a different important mechanism of action since oxidative damage can be caused by lipid- or water-soluble molecules. Lipid-soluble antioxidants are likely to be very important in preventing the peroxidation of low-density lipo-proteins (LDL) and this action could be paramount in the prevention of atherosclerosis. On the other hand, water-soluble antioxidants could be useful where a water-soluble oxidative stress occurs (e.g., inflammation). As lipophilic molecules, vitamin E and beta-carotene are incorporated into the LDL particle. Vitamin E is the main lipid-soluble chain-breaking antioxidant in plasma and tissues and converts the peroxyl-free radical to hydroperoxide, a less reactive radical. It acts as a first-line anti-oxidative defence of LDL particles, protecting unsatu-rated fatty acids from peroxidation. Beta-carotene is a carotenoid (precursor of vitamin A, pro-vitamin) that acts as scavenger of oxidising radicals such as singlet oxygen and is a second-line antioxidative defence of LDL cholesterol. Vitamin C (ascorbic acid) can react with singlet oxygen, superoxide, hydroxyl radicals, and is the first line of antioxi-dative defence in water-soluble compartments. In addition, it plays an important role in regenerating reduced -tocopherol.

• References

• 1 Violi F, Micheletta F, Iuliano L. Vitamin E atherosclerosis and thrombosis. Thromb Haemost 2001; 85: 766-70.
• 2 Steinberg D. and workshop participants.. Antioxidants in the prevention of human atherosclerosis. Circulation 1992; 85: 2337-44.
• 3 Marchioli R. Antioxidant vitamins and prevention of cardiovascular disease: Laboratory, epidemiological and clinical trial data. Pharmacol Res 1999; 40: 227-38.
• 4 Duthie GG, Wahle KWJ, James WPT. Oxidants, antioxidants and cardiovascular disease. Nutr Res Rev 1989; 2: 51-62.
• 5 Navab M, Berliner JA, Watson AD. et al. The yin and yang of oxidation in the development of the fatty streak: a review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996; 16: 831-42.
• 6 Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: A potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987; 84: 2995-8.
• 7 Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993; 328: 1444-9.
• 8 Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993; 328: 1450-6.
• 9 Kushi LH, Folsom AR, Prineas RJ. et al. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med 1996; 334: 1156-62.
• 10 Knekt P, Reunanen A, Jarvinen R, Seppanen R, Heliovaara M, Aromaa A. Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am J Epidemiol 1994; 139: 1180-90.
• 11 Nyssönen K, Parviainen MT, Salonen R, Tuomilehto J, Salonen JT. Vita-min C deficiency and risk of myocardial infarction: prospective population study of men from eastern Finland. BMJ 1997; 314: 634-8.
• 12 Blot WJ, Li JY, Taylor PR. et al. Nutrition intervention trials in Linixian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Nat Cancer Inst 1993; 85: 1483-92.
• 13 The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group.. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029-35.
• 14 Rapola JM, Virtamo J, Ripatti S. et al. Randomised trial of tocopherol and β-carotene supplements on the incidence of major coronary events in men with previous myocardial infarction. Lancet 1997; 349: 1715-20.
• 15 Virtamo J, Rapola JM, Ripatti S. et al. Effect of Vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch Intern Med 1998; 158: 668-75.
• 16 Lepälä JM, Virtamo J, Fogelhom R. et al. Controlled trial of tocopherol and β-carotene supplements on stroke incidence and mortality in male smokers. Arterioscler Thromb Vasc Biol 2000; 20: 230-5.
• 17 Törnwall ME, Vitamo J, Haukka JK. et al. Effect of tocopherol (vitamin E) and carotene supplementation on the incidence of intermittent claudication in male smokers. Arterioscler Thromb Vasc Biol 1997; 17: 3475-80.
• 18 Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347: 781-6.
• 19 GISSI-Prevenzione Investigators.. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354: P447-55.
• 20 The HOPE. (Heart Outcomes Prevention Evaluation) Study Investigators.. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 154-60.
• 21 Collaborative Group of the Primary Prevention Project (PPP).. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001; 357: 89-95.
• 22 Lonn EM, Yusuf S, Dzavik V, Doris I, Yi Q. et al for the SECURE Investigators.. Effects of ramipril and vitamin E on atherosclerosis. The study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103: 919-25.
• 23 Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U. et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356: 1213-8.
• 24 Dagenais GR, Marchioli R, Yusuf S, Tognoni G. Beta-carotene, vitamin C, and vitamin E and cardiovascular diseases. Curr Cardiol Rep 2000; 2: 293-9.
• 25 Iuliano L, Mauriello A, Sbarigia E, Spagnoli LG, Violi F. Radiolabeled native low-density lipoproteins injected into patients with carotid stenosis accumulates in macrophages of atherosclerotic pasque. Effect of vitamin E supplementation. Circulation 2000; 101: 1249-54.
• 26 Asmis R, Jelk J. Vitamin E supplementation of human macrophages prevents neither foam cell formation nor increased susceptibility of foam cells to lysis by oxidized LDL. Aterioscler Thromb Vasc Biol 2000; 20: 2078-86.
• 27 Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity, I: Clinical trials. Lancet 2001; 357: 373-80.
• 28 Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity, I: Observational studies. Lancet 2001; 357: 455-62.
• 29 Kromhout D. Protective nutrients and up to date dietary recommendations. Eur Heart J. 2001 (in press).
• 30 Weindruch R, Sohal RS. Caloric intake and aging. N Engl J Med 1997; 337: 987-94.